BHVN
$126.51
Biohaven Pharmaceutical Holding
$3.59
2.92%
BHVN
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($2.77)
Revenue:  $54.68 Mil
Monday
Aug 9
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BHVN reports earnings?
Beat
Meet
Miss

Where is BHVN's stock price going from here?
Up
Flat
Down
Stock chart of BHVN
Analysts
Summary of analysts' recommendations for BHVN
Score
Grade
Pivots
Resistance
$133.89
$130.53
$128.52

$125.16

Support
$123.15
$119.79
$117.78
Tweet
Growth
Description
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.